Mitochondrial-derived peptides: the signalling class behind MOTs-c

Until 2015, the textbook position was that the mitochondrial genome — the small ring of DNA tucked inside every mitochondrion — coded for almost nothing. A handful of proteins for the energy machinery and that was it.

That picture was wrong. Tucked inside that small mitochondrial genome are short open reading frames — stretches of DNA that, on a second look, code for short peptides nobody had noticed. Those peptides leave the mitochondria, enter the bloodstream, and act like hormones for metabolism. They are now a category — mitochondrial-derived peptides, MDPs — and the longevity market has spent the last few years buying the one with the most data.

What a mitochondrial-derived peptide actually is

Mitochondria are the small organelles inside almost every cell that produce most of the energy your body runs on. Each one has its own DNA — a tiny circular genome, separate from the larger nuclear genome that codes for most of your proteins. The mitochondrial genome was long assumed to be doing a narrow job: encoding a handful of components for the energy-production machinery.

A mitochondrial-derived peptide — MDP — is a short peptide whose code sits inside that mitochondrial genome, in a stretch of DNA that gets read and translated into a small product. The product gets exported out of the mitochondria, sometimes into the bloodstream, where it acts as a signal. The fact that the mitochondrial genome was making signals at all, rather than just energy-machinery parts, was a new biological category.

The class members named so far include MOTs-c — the first one formally characterised — plus the humanin family and the SHLP1–6 series. MOTs-c is the most-studied. Anything sold as a mitochondrial peptide on a research-chemical site is almost always MOTs-c.

How MOTs-c was discovered

In 2015, Lee and colleagues at USC published in Cell Metabolism that a 16-amino-acid peptide — sequence MRWQEMGYIFYPRKLR — was being encoded within the mitochondrial 12S rRNA gene. The peptide left the mitochondria, entered the bloodstream, and showed up in skeletal muscle, where it activated AMPK and improved glucose handling.

In mice fed a high-fat diet, MOTs-c administration reduced diet-induced obesity and improved insulin sensitivity. That was the seed. Follow-up work built the case for MOTs-c as a metabolic regulator and, in some hands, as a longevity-adjacent compound.

The animal mechanism story

In mice, MOTs-c activates AMPK signalling in skeletal muscle. AMPK is the master switch the body uses to coordinate fuel use — it tells cells to burn glucose and fat, hold off on building, and run the housekeeping programmes exercise also activates. Flipping it on, in a healthy animal, drives metabolic flexibility: better glucose handling, better fatty acid use, less fat storage.

Reynolds and colleagues in Nature Communications (2021) extended the story into ageing. They dosed aged mice with MOTs-c and watched grip strength and treadmill performance recover. The peptide also moved into the nucleus under stress and switched on adaptive gene-expression programmes — the same ones a tough workout activates in a younger animal. They called MOTs-c an exercise-induced mitochondrial-encoded regulator; the headlines compressed that to exercise mimetic. The original framing was narrower: one of the things exercise does is release this peptide, and giving it back to an old animal recovered some of what age took.

The MDP class story is similar in shape, but MOTs-c carries most of the data.

Why this matters for longevity — and where the framing breaks

The longevity argument runs like this. Circulating MOTs-c declines with age in humans. It tracks lower in people with obesity, type 2 diabetes, and metabolic syndrome. It correlates positively with fitness. The 2022 Mohtashami review in the International Journal of Molecular Sciences pulls that observational picture together. So if a peptide whose level falls with age is being given back to an ageing animal, and the animal does better, the inference that giving it back to an ageing human would also help is the obvious next step.

The inference is reasonable. It isn’t evidence. Observational data on circulating levels tells you the molecule is involved in the biology of ageing. It does not tell you that injecting it into a 50-year-old, twice a week, for six months, changes anything that matters. The trial that would settle that — randomised, placebo-controlled, in middle-aged adults — has not been run. The other MDPs sit further out on the same gradient: less data, no controlled human trials.

What the human file actually contains

The published human record on MOTs-c — and the MDP class more broadly — splits into two pieces. The bulk is observational: circulating levels measured across populations, correlated with age and metabolic health. The 2022 Mohtashami review is the cleanest summary of that.

The newer piece is small, randomised, and worth saying out loud. In 2025, Elhusseiny, Ihsan and colleagues published in Medicine & Science in Sports & Exercise a controlled trial in 19 active men: four weeks of supervised training, then two weeks of unilateral calf immobilisation, randomised between repeated heat exposure (n=9) and a sham condition (n=10). Repeated heat upregulated circulating MOTs-c (p=0.033). The sham didn’t move it. Immobilisation alone didn’t either.

The headline detail most coverage misses: nobody got injected with MOTs-c. The intervention was heat. The trial shows the mitokine pathway moves in humans — the precondition for the whole story being plausible at all. It doesn’t show that giving someone MOTs-c does anything.

The honest summary: the underlying mitokine biology is moving in people, exactly once, in a 19-person environmental-stress trial, without a peptide injection. Everything past that is still mouse-only.

The regulatory positioning

MOTs-c is among the bulk drug substances on the FDA Pharmacy Compounding Advisory Committee’s July 23, 2026 docket per Federal Register notice 2026-07361, with the FDA-reviewed uses listed as obesity and osteoporosis — not longevity, not exercise enhancement, neither of the consumer pitches.

The committee is being asked whether US-licensed pharmacies should be allowed to compound MOTs-c for obesity and osteoporosis on a doctor’s prescription. The longevity framing the off-label market sells on isn’t what’s under review. We covered how PCAC reviews actually work in What is the PCAC.

The other MDPs — humanin, the SHLPs — are not on the July 2026 or February 2027 dockets. MOTs-c is the only MDP-class member in the current FDA review window.

So where does the class actually sit

The mitochondrial-derived peptide class is a real and unusually clean piece of biology. Short peptides encoded inside the mitochondrial genome, acting as metabolic signals — a category that didn’t exist in textbooks a decade ago. MOTs-c, the most-studied member, has a coherent animal mechanism story, an observational human dataset, and a single small human trial in which the intervention was heat and not the peptide.

That is the kind of evidence you’d build a hypothesis around, not the kind you’d dose yourself on.

A controlled human trial of MOTs-c in middle-aged adults — randomised, placebo-controlled, longevity-adjacent endpoints — is the data this category needs and doesn’t have. Wolverine Health is being built around the version where that trial exists and a US-licensed pharmacy can dispense the result. Join the waitlist for a heads-up the day either of those conditions changes.